Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer

相似書籍

• First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
  由: Addeo, Alfredo, et al.
  出版: (2018)
• Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
  由: Chuang, Jody C., et al.
  出版: (2015)
• Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning
  由: Klempner, Samuel J., et al.
  出版: (2015)
• Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
  由: Sivignon, Marine, et al.
  出版: (2020)
• Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
  由: Marine Sivignon, et al.
  出版: (2020-01-01)